Its likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo Nordisks semaglutide is set to sit in second place
Great news for both patients, physicians and of course welcome news for Novo Nordisk now since FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)
The ads also say the claims havent been evaluated by the Food and Drug Administration
Independent baseline testing ensures you begin therapy with a complete clinical picture
Glutathione can be scheduled as a stand alone IV push or added to other infusion
Ozempic is a brand-name medication containing the active ingredient semaglutide